Increasing walking capacity in patients with peripheral artery disease
- PMID: 40169146
- DOI: 10.1016/S0140-6736(25)00574-4
Increasing walking capacity in patients with peripheral artery disease
Conflict of interest statement
JAB has consulted for JanOne, Medtronic, Merck, Mingsight, Novartis, Tourmaline, and Regeneron; is a member of the board of trustees of the VIVA Foundation; and is an editor of Braunwald's Vascular Medicine. MAC reports unrelated grants from the US National Institutes of Health (NIH NIGMS P20GM148278 and NIH NHLBI UG3HL169565-01A1) paid to his institution; royalties from Elsevier and Wolters Kluwers; and payment from Mosby for a book chapter.
Comment on
-
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.Lancet. 2025 May 3;405(10489):1580-1593. doi: 10.1016/S0140-6736(25)00509-4. Epub 2025 Mar 29. Lancet. 2025. PMID: 40169145 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources